Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05766254 · ClinicalTrials.gov registry record · NA
Identify the Optimal TMS Target to Modulate Reward Activity
A NA study of Nicotine Use Disorder, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05766254: Recruiting NA study of Nicotine Use Disorder, sponsored by Rutgers, The State University of New Jersey.
NCT05766254 is a NA study of Nicotine Use Disorder that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 36 participants, below the 98-participant average among 7 other Nicotine Use Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05766254, a NA study of Nicotine Use Disorder, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \[TCQ\]. We plan to accomplish these three objectives using a randomized, controlled experiment involving 3 sessions.
Primary Outcome
The reward positivity is an event-related brain potential (ERP) sensitive to reward feedback. The reward positivity will be measured during the T-maze task, where participants will receive feedback (Reward, No-reward) following choices. ERPs will be created for each electrode and participant by averaging the single-trial EEG according to feedback type (Reward, No-reward). The reward positivity will be evaluated by subtracting the Reward feedback ERPs from the corresponding No-reward feedback ERP
Conditions Studied
Interventions
- DEVICE Active 10-Hz TMS to the DLPFC
- DEVICE Sham TMS-DLPFC
Study Locations (1)
New Jersey
- Rutgers University - Newark - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05766254 shows while recruiting
NCT05766254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 98-participant average among 7 other Nicotine Use Disorder trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Nicotine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Active 10-Hz TMS to the DLPFC is the first listed.
NCT05766254 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05766254 about?
NCT05766254 is a clinical study titled "Identify the Optimal TMS Target to Modulate Reward Activity". Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the target...
What is the current status of trial NCT05766254?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2023-03-24. Estimated completion is 2026-09.
What conditions does trial NCT05766254 study?
This clinical trial studies the following conditions: Nicotine Use Disorder.
What interventions are being tested in trial NCT05766254?
The interventions under investigation include: Active 10-Hz TMS to the DLPFC (DEVICE), Sham TMS-DLPFC (DEVICE).
Who is sponsoring clinical trial NCT05766254?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05766254 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Novel E-cigarette Constituents on Adults TCORS 3.0
RECRUITING · NA
-
Identify the Optimal TMS Pulse Protocol to Modulate Reward Activity
RECRUITING · NA
-
Temporal Interference Methods for Addiction Treatment
RECRUITING · NA
-
Families With Substance Use and Psychosis: A Pilot Study
COMPLETED · NA
-
Acute Effects of TCIG vs ECIG in PLWH
COMPLETED · NA
-
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI